 I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will report financial results for the six months ended June 30, 2020 before the market opens on Monday, August 31, 2020, and host a conference call to discuss the results and provide a corporate update at 8:00 a.m. ET. 